SCHEDULE 14A INFORMATION

PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

Filed by the Registrant [x]

Filed by a Party other than the Registrant [ ]

Check the appropriate box:

[ ]Preliminary Proxy Statement

[ ]Confidential, for Use of the Commission Only (as permitted by Rule
   14a-6(e)(2))

[ ] Definitive Proxy Statement

[x] Definitive Additional Materials

[ ] Soliciting Material Pursuant to Section240.14a-11(c) or
    Section240.14a-12

                         SCICLONE PHARMACEUTICALS, INC.

                (Name of Registrant as Specified In Its Charter)



Payment of Filing Fee (Check the appropriate box):

[x] No fee required.

[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

      1)    Title of each class of securities to which transaction applies:

            ---------------------------------------------------------------

      2)    Aggregate number of securities to which transaction applies:

            ---------------------------------------------------------------

      3)    Per unit price or other underlying value of transaction computed
            pursuant to Exchange Act Rule 0-11 (set forth the amount on which
            the filing fee is calculated and state how it was determined):
            ---------------------------------------------------------------

      4)    Proposed maximum aggregate value of transaction:

            ---------------------------------------------------------------

      5)    Total fee paid:

            ---------------------------------------------------------------


[ ] Fee paid previously with preliminary materials.

[ ] Check box if any part of the fee is offset as provided by Exchange Act
    Rule 0-11(a)(2) and identify the filing for which the offsetting fee
    was paid previously. Identify the previous filing by registration
    statement number, or the Form or Schedule and the date of its filing.

      1)    Amount Previously Paid:

            ---------------------------------------------------------------


      2)    Form, Schedule or Registration Statement No.:

            ---------------------------------------------------------------

      3)    Filing Party:

            ---------------------------------------------------------------

      4)    Date Filed:

            ---------------------------------------------------------------

                   SCICLONE REAFFIRMS PROXY PROPOSALS DESIGNED

                    TO PROTECT AND ENHANCE SHAREHOLDER VALUE

San Mateo, CA, May 17, 2002 - SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN)
today reaffirmed that the proposals on the 2002 proxy statement are designed to
protect and enhance shareholder value, particularly as the Company continues to
progress with its late-stage clinical trials for its lead drug ZADAXIN(R) in the
U.S., Europe and Japan.

Donald R. Sellers, President and CEO of SciClone, commented, "We firmly believe
these proposals will protect and enhance the value of every shareholder's
investment in SciClone. We were contacted by Randal Kirk yesterday and declined
his offer to negotiate these proposals. Although we respect Randal Kirk and his
opinions, we believe he does not fully understand the proposals and we
profoundly disagree with his reported assessments. We respect all shareholders
equally, regardless of their individual holdings, and firmly believe these
proposals best represent the interests of all our shareholders."

A copy of SciClone's 2002 Proxy Statement which outlines the proposals and the
Board of Directors' reasons for support for these proposals is available in the
investor relations section of the Company's website at www.sciclone.com.

SciClone Pharmaceuticals' lead immune system enhancing drug ZADAXIN is approved
for sale in 27 countries and has been administered without clinically
significant side effects to patients for over 10 years. ZADAXIN is currently in
phase 3 hepatitis C clinical trials in the U.S., a phase 3 hepatitis B clinical
trial in Japan and in a phase 2-3 cancer program in Europe.

SciClone's strategic goal is to become the principal worldwide provider of
immune system enhancers as monotherapies and as critical components of
combination drug therapies for infectious diseases and cancer. Other drugs in
SciClone's pipeline are intended to protect and expand this franchise and to
address the protein-based disorder that causes cystic fibrosis.

Corporate information contact:
Richard A. Waldron, CFO
650-358-3437